Ma W, Peltzer K, Qi L, et al. - Whether and how the prevalence of bone metastases (BM) differs between the genders was investigated, and researchers also determined how female gender influences the development and prognosis of BM, by analyzing cases of invasive non-sex-specific cancers diagnosed between 2010 and 2015 from the Surveillance, Epidemiology, and End Results program. Among male and female patients, the pooled prevalence of BM was estimated to be 2.3% (95% CI: 1.6–3.2%) and 1.8% (95% CI: 1.2–2.6%), respectively. For patients aged 11–40 years old, a dramatic reduction in the pooled prevalence of BM was noted. It plateaued for patients aged 41–90 years old and increased for patients aged > 90 years old in both male and female patients. In many non-sex-specific cancers, fewer BM were reported in relation to female gender, and the influence was constant with alterations in age. A protective influence of female gender was seen exclusively on the prognosis of respiratory system cancers.